

POSTER PRESENTATION

Open Access

Effect of nanoencapsulation on the phenomenon of drug interaction between anti-*M.avium* drug, rifabutin and anti-HIV drug, ritonavir by employing poly (lactide-co-glycolide) nanoparticles

Tapinder Grewal*, Sadhna Sharma

From First International Science Symposium on HIV and Infectious Diseases (HIV SCIENCE 2012) Chennai, India. 20-22 January 2012

Background

Interaction between *M.avium* and HIV drugs is unavoidable in HIV patients as for an improved life expectancy of HIV patients, additional medications have to be administered along with HIV drugs. The anti-*M.avium* drug rifabutin and protease inhibitor, ritonavir are associated with significant drug interactions involving the cytochrome P450 (CYP) enzyme system. Little information is available on the role of various drug delivery strategies in alleviations of interactions between anti-*M. avium* and anti-HIV drugs. The purpose of the present study was to evaluate effect of encapsulation of rifabutin and ritonavir in PLGA nanoparticles on the already known drug interaction exhibited by these drugs.

Methods

This study was designed including administration of rifabutin and ritonavir singly and in combination in free and nanoencapsulated form to swiss albino mice. Blood samples were taken following drug administration at various time intervals and pharmacokinetic parameters were assessed as: area under plasma drug concentration over time curve (AUC0- ∞), mean residence time (MRT) and Cmax etc.

Results

Overall, nanoencapsulation was observed to avoid the known adverse drug interactions between RBT and RTV in the drug interaction study. (p-value<0.001).

* Correspondence: peace7grewal@yahoo.in Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Conclusion

Our results clearly emphasize the potential of the PLGA nanoparticle formulation to minimize drug interactions as the encapsulated drugs did not result in any significant alteration in kinetic parameters upon co-administration. It can be reasonably stated that nanoencapsulation would not only permit intermittent dosing but also a more favorable pharmacokinetics which further can overcome the drug interactions.

Published: 4 May 2012

doi:10.1186/1471-2334-12-S1-P13

Cite this article as: Grewal and Sharma: Effect of nanoencapsulation on the phenomenon of drug interaction between anti-M.avium drug, rifabutin and anti-HIV drug, ritonavir by employing poly (lactide-coglycolide) nanoparticles. BMC Infectious Diseases 2012 12(Suppl 1):P13.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



